TY - JOUR

T1 - Experimental models of cognitive impairments in schizophrenia

AU - Dorofeikova, M. V.

AU - Kutcher, E. O.

AU - Egorov, A. Yu

AU - Petrova, N. N.

N1 - Dorofeikova, M.V., Kutcher, E.O., Petrova, N.N. et al. Experimental Models of Cognitive Impairments in Schizophrenia. Neurosci Behav Physi 51, 765–773 (2021). https://proxy.library.spbu.ru:2060/10.1007/s11055-021-01133-y

PY - 2021

Y1 - 2021

N2 - Cognitive impairments in schizophrenia are currently regarded as the third key group of symptoms, along with negative and productive psychopathological symptomatology. They are encountered in a majority of patients and determine the functional outcome of illness. This article presents a review of the literature on modeling of cognitive impairments in schizophrenia in animals. Pharmacological, ontogenetic, and genetic models are discussed, along with their mechanisms and characteristic manifestations, and methods of evaluating cognitive functions in rodents. There is now a multitude of methods for modeling individual cognitive impairments typical of schizophrenia patients in animals. These models are required for further development of psychopharmacology and studies of pathophysiological mechanisms, though none as yet allows the whole set and heterogenous structure of cognitive defi cit seen in patients to be reproduced. Particular attention is paid to ontogenetic models which can be used to study risk factors for the development of schizophrenia and early interventions in states posing high risks of developing psychosis.

AB - Cognitive impairments in schizophrenia are currently regarded as the third key group of symptoms, along with negative and productive psychopathological symptomatology. They are encountered in a majority of patients and determine the functional outcome of illness. This article presents a review of the literature on modeling of cognitive impairments in schizophrenia in animals. Pharmacological, ontogenetic, and genetic models are discussed, along with their mechanisms and characteristic manifestations, and methods of evaluating cognitive functions in rodents. There is now a multitude of methods for modeling individual cognitive impairments typical of schizophrenia patients in animals. These models are required for further development of psychopharmacology and studies of pathophysiological mechanisms, though none as yet allows the whole set and heterogenous structure of cognitive defi cit seen in patients to be reproduced. Particular attention is paid to ontogenetic models which can be used to study risk factors for the development of schizophrenia and early interventions in states posing high risks of developing psychosis.

KW - cognitive defi cit

KW - cognitive functioning

KW - experimental modeling

KW - preclinical investigations

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85114631882&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/3c6ef22d-d860-3912-93ca-e63d1cdc7508/

U2 - 10.1007/s11055-021-01133-y

DO - 10.1007/s11055-021-01133-y

M3 - Article

AN - SCOPUS:85114631882

VL - 51

SP - 765

EP - 773

JO - Neuroscience and Behavioral Physiology

JF - Neuroscience and Behavioral Physiology

SN - 0097-0549

IS - 6

ER -